Catalyst Biosciences Inc
Performance History
| Key Stats | |
|---|---|
| Open | $6.90 |
| Prev. Close | $6.73 |
| EPS | -20.70 |
| Dividend | $0.00 |
| Next Earnings Date | Aug 14, 2023 |
| Dividend Yield % | 792.92% |
| Market Cap | $261.17M |
| PE Ratio | - |
| low | high | |
|---|---|---|
| Day Range | 6.87 | 6.90 |
| 52 Week Range | 0.19 | 8.69 |
| Ratios | |
|---|---|
| P/B Ratio | 0.53 |
| Revenue | - |
| Operating M. % | 0.00% |
| Earnings | -$44.24M |
| Earnings Growth % | - |
| EBITDA Margin % | - |
| ROE % | -269.01% |
| EPS | -20.70 |
Score Breakdown
All Score (63 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| CBIO | Market | |
|---|---|---|
| Value | 55 | 42 |
| Quality | 41 | 46 |
| Ownership | 16 | 39 |
| Growth | 89 | 44 |
| Dividends | 33 | 32 |
All Score (63 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Catalyst Biosciences Inc (CBIO)
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of liver fibrosis associated with a broad spectrum of chronic liver diseases in the United States and internationally. It develops Hydronidone, that has completed phase 1 clinical trial for the treatment of nonalcoholic steatohepatitis, a severe form of nonalcoholic fatty liver disease. The company was founded in 2002 and is headquartered in South San Francisco, California.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Nassim Usman Ph.D.
- Headquarters
- South San Francisco
- Employees
- 7
Keep an eye on Catalyst Biosciences Inc
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.